Reevaluation of anticancer drug efficacy: a systematic review and meta-analysis using restricted mean survival time (RMST) as an efficacy parameter

• Project/Area Number: 18K18416
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 90140:Medical technology assessment-related
• Research Institution: Kitasato University
• Principal Investigator: Kaneko Masayuki 北里大学, 薬学部, 助教 (90725326)
• Project Period (FY): 2018-04-01 – 2021-03-31
• Project Status: Completed (Fiscal Year 2020)
• Budget Amount: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000); Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2018: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
• Keywords: メタアナリシス

Outline of Final Research Achievements

The restricted mean survival time (RMST) has received attention in recent years as a measure for a time-to-event outcome because of its robustness and clinical interpretability. The aims of this study were to reevaluate the efficacy of anticancer drugs derived from a meta-analysis based on hazard ratio (HR) and generate new clinically meaningful information by using the difference in RMST as an alternative approach to the HR for measuring the efficacy.

Academic Significance and Societal Importance of the Research Achievements

先行研究でハザード比を用いたメタアナリシスにより報告された抗がん剤の治療効果に関して、新たにシステマティックレビューを行い、RMSTを指標としたメタアナリシスを実施した。その結果、抗がん剤の治療効果に関する新たな臨床的知見が示された。本研究の成果は、臨床現場における治療方針の選択の一助になるものと考える。

Research Products

• [Journal Article] Effect of PARP inhibitors as maintenance treatment on restricted mean survival time in platinum-sensitive recurrent ovarian cancer: a systematic review and meta-analysis (2021)
  • Author(s): Kaneko M
  • Journal Title: Ann Pharmacother Volume: － Issue: 1 Pages: 27-34
  • DOI: 10.1177/10600280211013489
  • Peer Reviewed